do glp 1 cause heart problems GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies GLP-1 medications are rewriting the

These are widely available and well-proven

Since control of diabetes and obesity are significant health outcome risk factors, it is conceivable that the shortages and high cost of GLP1 agonists will exacerbate existing health disparities. David Cutler, MD His perspective echoed what Ma told us, namely that [o]ne of the biggest bottlenecks with GLP-1RA access is cost and insurance. Even if a doctor prescribes [this type of drug], patients cannot obtain it if their insurance does not cover it, which could worsen disparities, especially for those with public insurance or in underserved populations, he also emphasized

Geremew Kassa M et al

Furthermore, Semaglutides formulation allows for less frequent dosing, typically once weekly, compared to Liraglutide, which is usually taken daily

R.et al (2014)

Like liraglutide, semaglutide incorporates an Aib substitution at the 8th position in place of Ala, which confers resistance to enzymatic degradation by DPP-4